<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104238">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959061</url>
  </required_header>
  <id_info>
    <org_study_id>NJCTTQ-01</org_study_id>
    <nct_id>NCT01959061</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Raltitrexed to Treat Advanced Colorectal Cancer</brief_title>
  <acronym>TACE</acronym>
  <official_title>Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Chia-tai Tianqing Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Chia-tai Tianqing Pharmaceutical</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      evaluate the efficacy and safety of Raltitrexed and oxaliplatin and lipiodol transcatheter
      arthrial chemoembolization for in refractory colorectal carcinoma with liver metastases.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>lesion</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change of the lesion size in liver</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change of ECOG Performance Status</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Raltitrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ralititrexed, 4mg, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>4mg, every 4 weeks,transhepatic arterial infusion</description>
    <arm_group_label>Raltitrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>100~150mg, every 4 weeks, transhepatic arterial infusion</description>
    <arm_group_label>Raltitrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipiodol</intervention_name>
    <description>5-20ml, every 4 weeks, hepatic artery embolization</description>
    <arm_group_label>Raltitrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed colorectal adenocarcinoma

          2. Disease limited to the liver Unresectable disease by surgery or other local therapies

          3. Age &gt;18 years

          4. ECOG performance status 0-2,Child pugh A or B

          5. Expected survival â‰¥ 3 months

          6. Adequate hematological, hepatic, and renal function

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Patients with severe organ dysfunction or failure

          3. With severe cardiovascular disease, or mental

          4. Extraliver metastases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced colorectal cancer of liver metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
